Present invention relates in general to neuroprotection and repair, which is related to Tau dysfunctions (including Alzheimer disease). The present invention describes the direct interaction between a kind of FKBP52 albumen and τ. It is related to the neurological disorder of Tau dysfunctions for preventing and treating more particularly, it relates to screen drug, comprises the steps of. A kind of determining ability) candidate compound, in order to adjust interaction polypeptide between tau and FKBP52 peptides and b) favorable selection adjusts the candidate compound of the interaction. Present invention finally relates to diagnosis, prognosis and monitoring analysis, the neurological disorders to be related to Tau dysfunctions.
